CA2885566C - Compositions and methods for increasing human growth hormone levels - Google Patents

Abstract

A nutritional supplement and a use thereof orally to increase endurance and fat metabolism in a human being, the nutritional supplement comprising: L-arginine; Oxo-proline;
L-lysine; N-acetyl L-cysteine; L-glutamine; and Schizonepeta aerial parts powder.

Description

COMPOSITIONS AND METHODS FOR INCREASING HUMAN GROWTH
HORMONE LEVELS
PRIORITY CLAIM
This application claims the benefit of the filing date of: United States Patent Application Serial Number 13/623,114, filed September 20, 2012, for "METHODS
FOR INCREASING HUMAN GROWTH HORMONE LEVELS"; United States Patent Application Serial Number 13/623,117, filed September 20, 2012, for "COMPOSITIONS FOR INCREASING HUMAN GROWTH HORMONE
LEVELS"; United States Patent Application Serial Number 13/623,118, filed September 20, 2012, for "METHODS FOR INCREASING ENDURANCE AND
FAT METABOLISM IN HUMANS"; and United States Patent Application Serial Number 13/623,112, filed September 20, 2012, for "COMPOSITIONS AND
METHODS FOR INCREASING HUMAN GROWTH HORMONE LEVELS."
TECHNICAL FIELD
Embodiments of the invention generally relate to compositions and methods for increasing human growth hormone (hGH) levels in healthy human beings and for increasing endurance and fat metabolism in humans.
BACKGROUND
The primary biological function of hGH includes stimulating growth, cell repair and regeneration. Once the growth period of adolescence concludes, the primary function of hGH in adulthood becomes that of cell regeneration and repair, helping to regenerate skin, bones, heart, lungs, liver and kidneys to their optimal, youthful cell levels. As is the case with many of our other hormones or their pre-cursors, such as testosterone, estrogen, progesterone, DHEA and melatonin, hGH levels decline with age. Therapeutically, many of these hormones can be replaced to offset some of the effects of aging such as menopausal symptoms in women or erectile dysfunction in men. The human body, like every other living entity, works on daily, or circadian, as well as monthly and annual rhythms. Daily growth hormone secretion diminishes with age with roughly half the levels at age forty that we had when we were twenty, and

-2-about one-third of those youthful levels at age sixty. In some sixty-year olds, the levels are as low as 25% of the hGH levels in a twenty-year old. Symptoms of aging include loss of muscle, increase of fat, decreased physical mobility, decreased energy levels and as a result, diminished socialization, diminished healing ability and an increased risk of cardiovascular disease and decreased life expectancy. Low hGH levels are associated with the aging process and early onset of disease. For example, Rosen and Bengtsson noted an increased death rate from cardiovascular disease in hGH
deficient patients (Rosen, T., Bengtsson, B. A., Lancet 336 (1990): 285-2880).
Until recently human growth hormone (hereinafter alternatively referred to as hGH) was available only in expensive injectable forms, and benefits from the restoration of hGH levels available only to those with the ability to pay.
Most recently natural substances that can trigger the release of human growth hormone from an individual's own anterior pituitary gland have become available. These are generically referred to as secretagogues. Secretagogues have the ability to restore hGH
levels, potentially to the levels found in youth. See for reference the book entitled "Grow Young With hGH" by Dr. Ronald Klatz, President of the American Academy of Anti-Aging, published in 1997 by Harper Collins.
HGH-deficient adults have marked reductions in lean body mass, and within months of hGH treatment, gains in lean body mass, skin thickness and muscle mass are observed. (Cuneo RC et al. J Appl Physiol 1991;70:695-700; Cuneo RC et al. J
Appl Physiol 1991;70:688-694; Rudman D et al. N Engl J Med 1969;280:1434-1438).
It is well-established that intravenous (IV) administration of some amino acids results in significant hGH secretion. Intravenous infusion of 183mg of argininelg body weight in females increased hGH levels >20-fold and 30g of arginine elevated serum hGH levels 8.6 fold in males. (Merimee TJ et al. N Engl J Med 1969;280:1434-1438; Alba-Roth J et al. J Clin Endocrinol Metab 1988;67:1186-1189).
Other amino acids, such as methionine, phenylalanine, lysine, histidine, and omithine have also led to marked increases in hGH (Alba-Roth, Muller, Schopohl, & von Werder, 1988; Chromiak & Antonio, 2002; Gourmelen, M., M. Donnadieu, et al.
(1972) Ann Endocrinol (Paris) 33(5): 526-528).
Given the difficulties in IV administration of amino acids for widespread use, interest in elucidating the hGH response to oral amino acid supplements prompted

-3-testing of such supplements containing mainly arginine, lysine and ornithine at varying amounts. Yet the pronounced variability in results among these studies, which differed in aspects including subject population, supplement composition, and dosage methodologies, make clear the complexities involved in the design of an effective supplement for supporting hGH levels in the general public. (Surninski RR et al. Int J
Sport Nutr 1997;7:48-60; Lambert MI et al. Int J Sport Nutr 1993;3:298-305;
Corpas E
et al. J Gerontol 1993;48:M128-M133; Isidori A et al. Curr Med Res Opin 1981;7:475-481; Fogelholm GM et al. Int J Sport Nutr 1993;3:290-297; Chromiak JA, Antonio J. Nutrition 2002 Jul;18(7-8):657-61).
Thus, determination of an effective and safe oral functional blend that stimulates hGH secretion in the general population is important to determine since athletes, entertainers and now the general public seek effective hGH support supplements and understand hGH to have rejuvenating properties.
Indeed, once partial to athletes and entertainers, the desire for effective supplements to provoke growth hormone (hGH) increases now extends to the general public. Not only do they have a goal of building lean tissue and reducing fat, but also in improving skin quality and other rejuvenating qualities that hGH is understood to provide. Despite proceeding literature on oral amino acids for use in stimulating hGH, evidence for an optimized oral amino acid-containing blend able to stimulate hGH in the general public including both men and women of a wide age range is not clear.
It would be desirable to provide a nutritional supplement for elevating hGH
release, in particular an amino acid-containing composition that is well tolerated having the result of increasing or elevating hGH release in those individuals whose hGH
release rates have slowed as a function of increasing age or that have normal hGH
levels but desire higher hGH levels. Although some existing nutritional supplements claim to impact the production of natural human growth hormone, there is a need for an improved nutritional supplement that efficiently enhances the production and effect of natural human growth hormone in the general population.
DISCLOSURE

3a In some embodiments, there is provided a use of a nutritional supplement orally to increase endurance and fat metabolism in a human being, the nutritional supplement comprising: 0.1 to 6 mmol L-arginine; 0.1 to 8 mmol Oxo-proline; 0.1 to 12 mmol L-lysine; 0.001 to 6 mmol N-acetyl L-cysteine; and 0.001 to 6 mmol L-glutamine.
In some embodiments, there is provided a use of a nutritional supplement orally to increase endurance and fat metabolism in a human being, the nutritional supplement comprising 3.44 mmol L-arginine; 5.30 mmol Oxo-proline; 8.21 mmol L-lysine; 6.13 pmol N-acetyl L-cysteine; and 6.84 [tmol L-glutamine.
In some embodiments, there is provided a nutritional supplement for use orally to increase endurance and fat metabolism in a human being, the nutritional supplement comprising: 0.1 to 6 mmol L-arginine; 0.1 to 8 mmol Oxo-proline; 0.1 to 12 mmol L-lysine; 0.001 to 6 mmol N-acetyl L-cysteine; and 0.001 to 6 mmol L-glutamine.
In some embodiments, there is provided a nutritional supplement for use orally to increase endurance and fat metabolism in a human being, the nutritional supplement comprising: 3.44 mmol L-arginine; 5.30 mmol Oxo-proline; 8.21 mmol L-lysine; 6.13 pmol N-acetyl L cysteine; and 6.84 [tmol L-glutamine.
The nutritional supplements described herein may also include schizonepeta.
Date Recue/Date Received 2020-11-10

-4-The present invention relates to a nutritional supplement and method of using the same. It is an amino acid-containing secretagogue composition, which, taken orally, stimulates the pituitary gland to increase serum levels of hGH.
Also described herein are nutritional supplement and method of using the same.
The nutritional supplement includes an amino acid secretagogue composition, which, taken orally, stimulates the pituitary gland to release hGH.
A particular embodiment of the present disclosure relates to an oral nutritional supplement that includes the amino acids 1-lysine, 1-arginine, oxo-proline, and one of either cysteine or glutamine. The amino acids may be delivered as non-toxic salts thereof, effective complexes thereof, stable chelates thereof, active esters thereof, functional derivatives thereof, and mixtures thereof which are effective to increase hGH levels in the general population.
Another particular embodiment relates to an oral nutritional supplement that consists essentially of 1-lysine HC1, 1-arginine HC1, oxo-prolinc, N-acety1-1-cysteine, 1-glutamine, and sehizonepeta (aerial parts) powder.
Other embodiments are drawn to methods of increasing human growth hormone in humans that include orally administering the disclosed nutritional supplement to a healthy human being. Alternative embodiments are drawn to methods of administering the disclosed nutritional supplements to a human being to improve endurance and fat metabolism.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows growth hormone levels after supplement administration compared to a placebo.
MODE(S) FOR CARRYING OUT THE INVENTION
The present invention relates to a method of use of a nutritional supplement by a human being. The nutritional supplement is an amino acid-containing secretagogue composition, which, taken orally, stimulates the pituitary gland to produce hGH.
Increased production of hGH may result in inhibition of insulin depression, inhibition of hyperglycemia and increase in insulin effectiveness, enhancement of fat conversion,

-5-lowering of cholesterol, and normalization of lipid balance. The supplement of the present invention works as a dietary supplement by assisting the body's own ability to secrete hGH naturally in a manner which is safe and effective, as well as being affordable.
A particular embodiment of the present disclosure relates to an oral nutritional supplement that includes 1-lysine, 1-arginine, oxo-proline, and one of either cysteine or glutamine. The supplement may additionally include both cysteine and glutamine and/or schizonepeta powder. In particular embodiments, a functional dosage includes the 1-arginine at a level between 0.1-6 mmol and the oxo-proline between 0.1-8 mmol, and/or the 1-lysine in an amount between 0.1-12 mmol. The cysteine and/or glutamine may be contained at a level between 0.001-6 mmol. In another particular embodiment, a functional dosage includes the 1-arginine at a level between 2.5-4.5 mmol and the oxo-proline between 4-6 mmol, and/or the 1-lysine in an amount between 7-9 mmol.
The cysteine and/or glutamine may be contained at a level between 0.001-0.5 mmol.
The cysteine can be n-acetyl L-cysteine and the glutamine may be 1-glutamine.
The amino acids may be delivered as non-toxic salts thereof, effective complexes thereof, stable chelates thereof, active esters thereof, functional derivatives thereof, and mixtures thereof which are effective to increase hGH levels in the general population.
The nutritional supplement may be present in an amount of 2.9 grams. The nutritional supplement may be in any acceptable and known oral formulation, such as powder, tablet, capsule, liquid, or wafer form.
Another particular embodiment relates to an oral nutritional supplement that consists essentially of 1-lysine HC1, 1-arginine HC1, oxo-proline, N-acetyl-l-cysteine, 1-glutamine, and schizoncpeta (aerial parts) powder. In particular embodiments, a functional dosage includes the 1-arginine HC1 at a level between 0.1-6 mmol and the oxo-proline between 0.1-8 mmol, and/or the 1-lysine HC1 in an amount between 0.1-12 mmol. The n-acetyl L-cysteine and/or 1-glutamine may be contained at a level between 0.001-6 mmol. In another particular embodiment, a functional dosage includes the 1-arginine HC1 at a level between 2.5-4.5 mmol and the oxo-proline between 4-6 mmol, and/or the 1-lysine HCl in an amount between 7-9 mmol. The n-acetyl L-cysteine and/or 1-glutamine may be contained at a level between 0.001-0.5 mmol.

-6-The nutritional supplement may be in any acceptable and known oral formulation, such as powder, tablet, capsule, liquid, or wafer form.
Other embodiments are drawn to methods of increasing human growth hormone in humans that include orally administering the disclosed nutritional supplement to a healthy human being. As used herein, "healthy human being"
means a human being without any physiological deficiency in hGH independent of age.
Particular embodiments of the invention relate to oral administration of the disclosed nutritional supplement to a human that is at least 30 years old. The nutritional supplement may be administered from one to three times daily or, alternatively, may be administered every other day, or may be administered once a week. In particular embodiments, the nutritional supplement may be administered on an empty stomach.
The disclosed nutritional supplements can be orally administering to a human being to improve health, including by improving endurance and increasing fat metabolism. The disclosed nutritional supplements can also be used in combination with testosterone or testosterone-boosting supplements to enhance the effect of the nutritional supplements disclosed herein.
In accordance with the "consist essentially of" and "consisting essentially of"
language, the nutritional supplement of the third embodiments is essentially limited to the aforementioned ingredients and does not include any additional active ingredients intended to add nutritional content (e.g., vitamins, minerals, etc.), but may include additional ingredients not intended to add nutritional content such as ingredients intended to fulfill a non-nutritional purpose (e.g., coloring, fillers, flavoring, an ingredient for maintaining the structural form, etc.).
Each ingredient of the nutritional supplement of the present invention may be prepared in accordance with any method known to one of ordinary skill in the art.
Alternatively, each ingredient may be obtained in a fully prepared from a commercially available source.
The nutritional supplement of the present invention may be in any suitable oral administration form, including but not limited to: a chewable form, a liquid form, a spray form, a capsule form, a suppository form, dissolvable wafer, and a powder form.

-7-Irrespective of the structural form of the nutritional supplement, the ingredients of the nutritional supplement may be distributed homogeneously or non-homogeneously within the nutritional supplement.
The nutritional supplement of the present invention may be ingested on a regular basis, such as a daily or weekly intake at a dosage tailored to an individual's needs; i.e., the nutritional supplement is to be taken regularly as multiples (lx, 2x, etc.) of the structural units (pills, tablets, capsules, liquid dose, etc.) in accordance with the needs of the individual. For example, a senior citizen leading a sedentary life may need higher daily doses than does a young person engaged in regular strenuous exercise (e.g., a weight lifter). Alternatively, the nutritional supplement of the present invention may be ingested on an as-needed basis at a dosage tailored to the individual's needs.
Medical or nutritional counseling may be beneficial for arriving at a desirable or optimal dosage tailored to the individual's needs.
The combination of types of amino acids, mass ranges, and specific formulations have been selected to be synergistically balanced and of adequate quantity to achieve the desired physiological effect, namely, growth hormone release.
Improper combinations of the amino acids may be ineffective. The component amino acids are synergistic in the sense that several of them when combined together, synergistically stimulate the release of human growth hormone. The combination was also chosen to reduce or inhibit chemical combination or reaction between the amino acids.
EXAMPLES
Example 1 A cross-over, placebo controlled, double-blind study involved 16 healthy subjects [12 males, 4 females; 9 Caucasian, 6 African American, 1 other; mean age= 32 14 years; body mass index=26.4 5.0 ranging from 19.1 to 36.8kg/m2].
Each subject reported to the Inpatient Unit on two occasions one week apart. After an overnight fast, subjects had an IV line placed and baseline bloods samples were drawn at -30, -15, and 0 minutes. Subjects were then asked to swallow the capsules of the test supplement or an identical looking placebo.

-8-The administered supplement is a novel 2.9g/dose blend of 1-lysine HC1, 1-arginine HC1, oxo-proline, N-acetyl-l-cysteine, 1-glutamine, and schizonepeta (aerial parts) powder.
Blood was drawn at 15, 30, 60 and 90 and 120 minutes for assay. Human GH
was measured at each time point using the Siemens Immulite 2000 (infra-assay CV
was 3.72%, inter-assay CV was 5.70%, and the detection limit for GH was 0.05ng/ml.
Mean growth hormone increased eight-fold over baseline (equivalent to 682%) after the supplement from 0.17 at baseline to 1.33ng/m1 at 120 minutes compared to a mean decrease of 52% after placebo from 0.93 to 0.45ng/m1 (FIG. 1). The mean change in GH levels from baseline to 120 minutes (GH at 120 minutes minus GH
at 0 minutes), was 1.15 (95% CI: 0.17, 2.14) ng/ml after the supplement versus -0.48 (-1.47, 0.50) ng/ml after the placebo, demonstrating a statistically significant differential effect (P=0.01). After the supplement, the mean AUC for GH across 120 minutes was 20.43 (95% CI: 19.90, 20.95) ng/ml/min which was significantly higher (P=0.04) than placebo at 19.67 (18.74, 20.59) ng/ml/min. Overall, 120 minutes after taking the supplement, GH levels were significantly higher in both absolute levels and by AUC.
Mean levels of GH reached after the subcutaneous injection of 0.06 IU of HGH
in the treatment of GH deficient subjects was 0.4ng/ml, a value that was clearly in the range of values seen in our study with oral amino acids (Janssen YJ et al. Br J Clin Pharmacol 1999;47:273-278).
The present study is distinct in that it had a broad range of ages and BMI's and included both genders. An additional advantage of this study of the amino-acid containing blend over previous hGH evaluations is that it contained a placebo control group and was randomized and double-blinded.
Example 2 The short-term effects of a single oral nutritional supplement on hGH levels 2 hours post ingestion was studied 16 healthy subjects [12 males, 4 females;

9 Caucasian, 6 African American, 1 other; mean age= 32 14 years; body mass index=26.4 5.0 ranging from 19.1 to 36.8kg/m21. Each subject reported to the Inpatient Unit on two occasions one week apart. After an overnight fast, subjects had an W line placed and baseline bloods samples were drawn at -30, -15, and 0 minutes.
Subjects were then asked to swallow the capsules of supplement (SER0VITAL ) or an identical looking placebo. SEROVITAL is a 2.9g/dose blend of 1-lysine HC1, 1-arginine HCL, oxo-proline, N-acetyl-l-cysteine, 1-glutamine, and schizonepeta (aerial parts) powder. Blood was drawn at 15, 30, 60 and 90 and 120 minutes for assay. Human GH was measured at each time point using the Siemens Immulite 2000 (intra-assay CV was 3.72%, inter-assay CV was 5.70%, and the detection limit for GH was 0.05ng/ml. The -15 and 120 minute time points were additionally assayed for triiodothyronine (T3) as informative for mechanistic investigations.
The mean growth hormone increased 682% after the supplement from 0.17 at baseline to 1.33ng/m1 at 120 minutes compared to a mean decrease of 52% after the placebo from 0.93 to 0.45ng/m1 (FIG. 1).
The mean change in GH levels from baseline to 120 minutes (GH at 120 minutes minus GH at 0 minutes), was 1.15 (95% CI: 0.17, 2.14) ng/m1 after the supplement versus -0.48 (-1.47, 0.50) ng/ml after the placebo, demonstrating a statistically significant differential effect (P=0.01). After the supplement, the mean AUC for GH across 120 minutes was 20.43 (95% CI: 19.90, 20.95) ng/ml/min, which was significantly higher (P=0.04) than placebo at 19.67 (18.74, 20.59) ng/ml/min.
Overall, 120 minutes after taking the supplement, GH levels were significantly higher in absolute levels or by AUC.
As daily circadian levels of T3 naturally decrease during the morning hours, at which the current trial was scheduled, it was not surprising that placebo levels between the -15 and 120 minute time points decreased by -6.10 ng/dL (106 to 100 ng/dL, P=0.01). In contrast, the SERoViTALER) group exhibited a deceased reduction inT3 by nearly one-half over the same time course, -3.3 ng/dL (101-97.3 ng/dL, NS), which was not a significant reduction compared to baseline, as was the reduction in the placebo group. These results affirm that somatostatin inhibition plays a mechanistic role in the ability of SER0VITALO to induce significant increases in serum GH
levels in human subjects.

-10-At 120 minutes, GH concentrations were 2-fold higher in women (2.3 1.1ng/ml, n=4) than in men (1.0 0.4 ng/ml, n= 12, although the study was not adequately powered for these comparisons. Nevertheless, these findings support an enhanced effect of the SERoVITALO supplement in women.
An eight-fold increase was observed, equivalent to 682%, in GH levels 120 minutes after a single oral supplement of SER0VITALO. The study had a broad range of ages and BMI's and included both genders. An additional advantage of the present study over previous GH evaluations is that it contained a placebo control group and was randomized and double-blinded.
These findings demonstrate that a specialized low-dose amino acid supplement can significantly increase short-term GH levels. Future studies will examine whether such increases in GH with oral amino acid supplementation increase fat-free mass and strength. This indeed may be the case, since elderly subjects administered oral GH
secretagogues for 6 and 12 months have sustained increases in lean body mass and improved physical function.
The absolute magnitudes of these results are somewhat difficult to directly correlate among past studies, as commercial GH assays use different antibodies to target specific GH epitopes. Therefore, different antibodies and assays are less likely to recognize some specific isoforms and fragments of the GH molecule. This results in variability of the normal range of the GH measurements in different assays.
Indeed, the same GH sample measured using different assays can vary 2-3 fold, limiting the ability to compare actual GH levels across studies. Nevertheless, the mean levels of GH reached after the subcutaneous injection of 0.06 IU of HGH in the treatment of GH
deficient subjects was 0.4ng/ml, a value that was clearly in the range of values seen in our study with oral amino acids.
Findings obtained from a randomized, blinded, placebo-controlled study strengthen the evidence that oral administration of amino acids, when compounded properly, can increase GH serum levels, wherein SERDVITALO administration showed an 8-fold, equivalent to a 682% increase in GH levels 120 minutes after a single oral dose. In addition, we elucidate some mechanistic details for these significant GH
increases as through somatostatin inhibition, supported by our results on the 120 minute results on T3 levels in the same subjects.

-11-Example 3 To test the effect of the nutritional supplement on endurance and fat metabolism, a double-blind clinical study was conducted involving 12 healthy subjects [7 males, 5 females; mean age = 31 6 years; body mass index= 25.7 3.8 ranging from 20.3 to 32.2 kg/m2]. Each subject reported to the Fitness Testing Facility (PEAK, University of Utah College of Health) after an overnight fast. Upon arrival each subjects underwent standard measurements of weight, height, body fat percent (Bod Pod), and resting metabolic rate (RMR, indirect calorimerty). Daily calorie expenditure was estimated based on the additive evaluations of measured RMR, estimated Lifestyle and Activity (defined as the number of calories burned performing daily activities including working, playing eating, etc.), and estimated Exercise (defined as an estimate of the number of calories burned during exercise based on daily activity level).
Following the baseline measurements, subjects then consumed a standard breakfast (Egg McMuffin, 300 Calories; 12g fat; 29g carbohydrates; 18g protein).
Subjects rested for a further 45 min to reach a post-absorptive state, then underwent a Maximal Aerobic Fitness Test of graded exercise, completed on a treadmill. Subjects' oxygen uptake was measured using a metabolic cart, and V02max was quantified.
Subjects were then provided a two week supply of a novel supplement StRoVITALO (2.9g/dose blend of 1-lysine HC1, 1-arginine HCl, oxo-proline, N-acetyl-l-cysteine, 1-glutamine, and schizonepeta (aerial parts) powder). The novel SERDVITALO blend has been shown previously to increase serum human growth hormone hGH levels by 8 times (equivalent to 682%) 120 minutes after a single dose in healthy male and female volunteers. In this study, subjects were instructed to consume one dose of the supplement on an empty stomach, two hours after dinner prior to bedtime, every night for the two-week study duration. Following the final dose, each subject returned to the PEAK Fitness Testing Facility, University of Utah College of Health after an overnight fast (without having consumed their last dose of the supplement since the previous night). Upon arrival each subjects underwent the identical test protocols as the baseline test day. The data from the two measurement days were then analyzed. Consistent with our priori hypothesis that the supplement would increase improve endurance parameters with its ability to increase in hGH

-12-levels, the decision was made to reject the null only if the data supported the one directional alternative consistent with a favorable response to the supplement.
Statistical significance was assumed for P<0.05.
Mean V02max increased by 6% from 44.9 8.1 at baseline to 47.7 9.2mL/kg/min (3.69 0.96 to 3.91 1.02L/min), demonstrating a statistically significant differential effect compared to baseline (P=0.02). After the period of supplementation with SERoViTALO, the mean RMR increased by 2.7% from 1687 330 to 1733 288kcaUday with a statistical trend towards significance compared to baseline (P=0.165). Estimated daily calorie expenditure also increased by 2.7%
from 1687 330 to 1733 288kca1/day with trend towards significance (P=0.166).
After two weeks of supplementation with the supplement SER0VITALO, (taken on an empty stomach, two hours after dinner prior to bedtime, every night), both RMR
and estimated daily calorie expenditure tended to increase, evidencing the potential of the supplement to impart long-term fat burning effects. Additionally, endurance as measured by VO2max in the post-absorptive state significantly improved with a measured 6% increase. Overall, the SERoViTALO supplement was shown to increase parameters of endurance, energy, and vitality.
While embodiments of the present invention have been described herein for purposes of illustration, many modifications and changes will become apparent to those skilled in the art. Accordingly, the appended claims are intended to encompass all such modifications and changes as fall within the true spirit and scope of this invention

Claims (19)

CLAIMS:

1. Use of a nutritional supplement orally to increase endurance and fat metabolism in a human being, the nutritional supplement comprising:
0.1 to 6 mmol L-arginine;
0.1 to 8 mmol Oxo-proline;
0.1 to 12 mmol L-lysine;
0.001 to 6 mmol N-acetyl L-cysteine; and 0.001 to 6 mmol L-glutamine.

2. The use according to claim 1, wherein the nutritional supplement is for administration from one to three times daily.

3. The use according to claim 1 or 2, wherein the nutritional supplement is for administration once a week.

4. The use according to any one of claims 1 to 3, wherein the nutritional supplement is for administration on an empty stomach.

5. The use according to any one of claims 1 to 4, wherein the human being is a healthy female human.

6. The use according to any one of claims 1 to 4, wherein the human being is a healthy male human that is at least 30 years of age.

7. Use of a nutritional supplement orally to increase endurance and fat metabolism in a human being, the nutritional supplement comprising:
3.44 mmol L-arginine;
5.30 mmol Oxo-proline;
8.21 mmol L-lysine;
Date Recue/Date Received 2020-11-10 6.13 prnol N-acetyl L-cysteine; and 6.84 umol L-glutamine.

8. The use according to claim 7, wherein the nutritional supplement is to be used in an amount of 2.9 grams.

9. The use according to claim 7 or 8, wherein the nutritional supplement is in powder, tablet, capsule, liquid, or wafer form.

10. The use according to any one of claims 7 to 9, wherein the nutritional supplement is for administration from one to three times daily.

11. The use according to any one of claims 7 to 10, wherein the nutritional supplement is for administration once a week.

12. The use according to any one of claims 7 to 11, wherein the nutritional supplement is for administration on an empty stomach.

13. The use according to any one of claims 7 to 12, wherein the human being is at least 30 years old.

14. A nutritional supplement for use orally to increase endurance and fat metabolism in a human being, the nutritional supplement comprising:
0.1 to 6 mmol L-arginine;
0.1 to 8 mmol Oxo-proline;
0.1 to 12 mmol L-lysine;
0.001 to 6 mmol N-acetyl L-cysteine; and 0.001 to 6 mmol L-glutamine.
Date Recue/Date Received 2020-11-10

15. A nutritional supplement for use orally to increase endurance and fat metabolism in a human being, the nutritional supplement comprising:
3.44 mmol L-arginine;
5.30 mmol Oxo-proline;
8.21 mmol L-lysine;
6.13 Ilmol N-acetyl L-cysteine; and 6.84 Ilmol L-glutamine.

16. The use according to any one of claims 1 to 6, wherein the nutritional supplement further comprises schizonepeta.

17. The use according to any one of claims 7 to 13, wherein the nutritional supplement further comprises schizonepeta.

18. The nutritional supplement according to claim 14, which further comprises schizonepeta.

19. The nutritional supplement according to claim 15, which further comprises schizonepeta.
Date Recue/Date Received 2020-11-10